BridgeBio Pharma, Inc. Prepaid Expense and Other Assets, Current
BridgeBio Pharma, Inc. (BBIO) had Prepaid Expense and Other Assets, Current of $65.65 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-10
- 2026-06-30: Prepaid Expense and Other Assets, Current $65.65M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $62.91M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $44.07M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $52.40M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $65.65M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $62.91M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $44.07M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $52.40M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $60.24M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $35.35M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $34.87M 10-K · filed 2026-02-24 | $34.74M 10-K · filed 2025-02-20 |
| 2024-09-30 | $38.37M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $28.40M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $28.11M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $24.30M 10-K · filed 2025-02-20 | |
| 2023-09-30 | $22.58M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $20.55M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $25.14M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $21.92M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $25.66M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $32.75M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $34.02M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $32.27M 10-K · filed 2023-02-23 | $32.45M 10-K · filed 2022-02-25 |
| 2021-09-30 | $31.93M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $26.67M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $25.53M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $35.73M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $26.70M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $21.00M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $19.78M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $19.78M 10-K · filed 2021-02-25 | $22.63M 10-K · filed 2020-03-03 |
| 2019-09-30 | $22.10M 10-Q · filed 2019-11-08 | |
| 2018-12-31 | $9.14M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |